The specific manufacturer of Tofacent 5 mg is currently:
- Tofacent 5 mg contains tofacitinib citrate equivalent to 5 mg of tofacitinib and is manufactured by Incepta Pharmaceuticals Ltd.
- Tofacitinib is an oral Janus kinase (JAK) inhibitor used for certain inflammatory and autoimmune diseases.
- The approved indications and dosing can vary by regulatory authority and patient factors, so the page should avoid presenting every use as universally approved.
- The statement about combining it with “heavy immunosuppressants” is too vague. More precise wording should mention that tofacitinib generally should not be combined with biologic DMARDs or potent immunosuppressants such as azathioprine or cyclosporine, unless specifically directed by a specialist.
- Because tofacitinib can increase the risk of serious infections, blood clots, cardiovascular events, and certain malignancies, the safety section should be more comprehensive.
- For authenticity, batch number, expiry date, packaging, and purchase source alone cannot definitively establish that a medicine is genuine. The manufacturer or licensed pharmacist/distributor is the appropriate source for verification.
It should not be assumed that Pfizer manufactures Tofacent simply because Pfizer developed tofacitinib and markets XELJANZ.
Pfizer’s documented role is that of the originator/developer and reference-product company associated with XELJANZ.
The company manufacturing Tofacent should be identified only after reviewing the product’s packaging, registration record, official manufacturer documentation or another reliable regulatory source.
Manufacturer identity
The manufacturer of the specific Tofacent product is Incepta Pharmaceuticals Ltd..
Authentication systems
No Tofacent-specific QR authentication system, serial-number database or online verification portal should be claimed unless documentation from the manufacturer or applicable regulator establishes that system.
Suspicious packaging
If a product appears damaged, altered, incorrectly labeled or inconsistent with legitimate pharmaceutical packaging, the concern should be discussed with a pharmacist, healthcare professional, authorized supplier or appropriate medicines regulator.
Counterfeit medicines
Falsified medicines may contain the wrong ingredient, incorrect strength, contaminants or no active pharmaceutical ingredient. A legitimate and appropriately regulated supply chain is an important part of medicine safety.